These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 20864814)

  • 41. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
    Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
    Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial.
    Sandberg JT; Löfling M; Varnaitė R; Emgård J; Al-Tawil N; Lindquist L; Gredmark-Russ S; Klingström J; Loré K; Blom K; Ljunggren HG
    PLoS Negl Trop Dis; 2023 Feb; 17(2):e0010616. PubMed ID: 36758067
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
    Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
    Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity & safety of a single dose of live-attenuated Japanese encephalitis vaccine SA 14-14-2 in adults.
    Khan SA; Kakati S; Dutta P; Chowdhury P; Borah J; Topno R; Jadhav SM; Mohapatra PK; Mahanta J; Gupte MD
    Indian J Med Res; 2016 Dec; 144(6):886-892. PubMed ID: 28474625
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Next generation yellow fever vaccine induces an equivalent immune and transcriptomic profile to the current vaccine: observations from a phase I randomised clinical trial.
    Pagnon A; Carre C; Aguirre M; Chautard E; Gimenez S; Raynal F; Feroldi E; Scott P; Modjarrad K; Vangelisti M; Mantel N
    EBioMedicine; 2024 Oct; 108():105332. PubMed ID: 39293214
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand.
    Chotpitayasunondh T; Sohn YM; Yoksan S; Min J; Ohrr H
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S195-203. PubMed ID: 22043776
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and immunogenicity of live-attenuated Japanese encephalitis SA 14-14-2 vaccine co-administered with measles vaccine in 9-month-old infants in Sri Lanka.
    Wijesinghe PR; Abeysinghe MR; Yoksan S; Yao Y; Zhou B; Zhang L; Yaich M; Neuzil KM; Victor JC
    Vaccine; 2014 Aug; 32(37):4751-7. PubMed ID: 24951871
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand.
    Chotpitayasunondh T; Pruekprasert P; Puthanakit T; Pancharoen C; Tangsathapornpong A; Oberdorfer P; Kosalaraksa P; Prommalikit O; Tangkittithaworn S; Kerdpanich P; Techasaensiri C; Korejwo J; Chuenkitmongkol S; Houillon G
    Vaccine; 2017 Jan; 35(2):299-304. PubMed ID: 27903416
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.
    da Costa-Rocha IA; Machado KLLL; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; de Lima SMB; Miranda EH; Trindade GF; Casagrande TZ; Miyamoto ST; Deotti SC; Barbosa RVR; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Valim V; Martins-Filho OA
    Sci Rep; 2021 May; 11(1):10431. PubMed ID: 34001945
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.
    Monath TP; Lee CK; Julander JG; Brown A; Beasley DW; Watts DM; Hayman E; Guertin P; Makowiecki J; Crowell J; Levesque P; Bowick GC; Morin M; Fowler E; Trent DW
    Vaccine; 2010 May; 28(22):3827-40. PubMed ID: 20347059
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Persistence of IgM Antibodies after Vaccination with Live Attenuated Japanese Encephalitis Vaccine.
    Hills SL; Van Keulen A; Feser J; Panella A; Letson GW; Staples JE; Marfin AA; Brault AC
    Am J Trop Med Hyg; 2020 Nov; 104(2):576-579. PubMed ID: 33236716
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
    Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
    Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.
    Monath TP; Nichols R; Archambault WT; Moore L; Marchesani R; Tian J; Shope RE; Thomas N; Schrader R; Furby D; Bedford P
    Am J Trop Med Hyg; 2002 May; 66(5):533-41. PubMed ID: 12201587
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is a booster dose necessary in children after immunization with live attenuated Japanese encephalitis vaccine?
    Choi UY; Lee SY; Kim KH; Kim DS; Choi KM; Cha SH; Kang JH
    J Trop Pediatr; 2013 Oct; 59(5):423-5. PubMed ID: 23764540
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity of a Live Attenuated Chimeric Japanese Encephalitis Vaccine as a Booster Dose After Primary Vaccination With Live Attenuated SA14-14-2 Vaccine: A Phase IV Study in Thai Children.
    Sricharoenchai S; Lapphra K; Chuenkitmongkol S; Phongsamart W; Bouckenooghe A; Wittawatmongkol O; Rungmaitree S; Chokephaibulkit K
    Pediatr Infect Dis J; 2017 Feb; 36(2):e45-e47. PubMed ID: 27846060
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
    Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
    BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?
    Michel R; Berger F; Ravelonarivo J; Dussart P; Dia M; Nacher M; Rogier S; Moua D; Sarr FD; Diop OM; Sall AA; Baril L
    Vaccine; 2015 May; 33(20):2301-6. PubMed ID: 25843268
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A single dose of vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines.
    Erra EO; Askling HH; Rombo L; Riutta J; Vene S; Yoksan S; Lindquist L; Pakkanen SH; Huhtamo E; Vapalahti O; Kantele A
    Clin Infect Dis; 2012 Sep; 55(6):825-34. PubMed ID: 22696017
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India.
    Bonaparte M; Dweik B; Feroldi E; Meric C; Bouckenooghe A; Hildreth S; Hu B; Yoksan S; Boaz M
    BMC Infect Dis; 2014 Mar; 14():156. PubMed ID: 24656175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.